Soluble TGF-beta Receptor II Isoform Modulates Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TGF-β dysregulation-related diseases, such as osteoarthritis and cancer, lack effective methods to modulate TGF-β signaling, leading to inadequate control over bone remodeling and angiogenesis, and existing TGF-β inhibitors can have adverse effects on joint cartilage and bone health.
Innovation Solution
A soluble isoform of the TGF-beta II receptor (TβRII-SE) lacking a transmembrane domain, which acts as a TGF-β1 agonist, is developed, comprising a specific amino acid sequence, and is used to treat diseases associated with TGF-β dysregulation by modulating TGF-β signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TGF-β inhibitors are used to treat TGF-β dysregulation-related diseases, then TGF-β signaling is blocked, but joint cartilage and bone health deteriorate
Solution Approach 1:
Instead of using inhibitors to block TGF-β signaling (conventional approach), the patent employs a soluble TβRII isoform that acts as a dominant-negative receptor to sequester TGF-β ligands, thereby indirectly modulating signaling without direct inhibition. This inverted approach allows control of TGF-β activity while preserving bone and cartilage health by maintaining physiological ligand availability for membrane-bound receptors in these tissues.
Solution Approach 2:
The soluble TβRII isoform serves as an intermediary molecule that binds TGF-β ligands in circulation and prevents their interaction with membrane-bound receptors in non-target tissues. This mediator approach allows selective modulation of TGF-β signaling in specific disease contexts while preserving beneficial signaling in bone and cartilage, resolving the contradiction between signaling control and tissue health.
2Productivity
If TGF-β1 concentrations are high to promote bone remodeling, then osteoblast and osteoclast activity increases, but osteoarthritis development accelerates
Solution Approach 1:
The soluble TβRII isoform enables local quality control of TGF-β signaling by selectively modulating ligand availability in specific tissue compartments. In subchondral bone, the soluble receptor can be administered to control excessive TGF-β activity driving osteophyte formation, while membrane-bound receptors in articular cartilage and healthy bone maintain normal physiological signaling. This spatially differentiated control resolves the contradiction between productive bone remodeling and harmful osteoarthritis progression.
3Object-affected harmful factors
If TGF-β signaling is inhibited to prevent osteophyte formation, then cartilage degradation is reduced, but bone volume decreases
Solution Approach 1:
The soluble TβRII isoform creates a copy of the TGF-β receptor that circulates in the bloodstream and binds TGF-β ligands before they reach target tissues. This soluble copy allows selective interference with pathological TGF-β signaling (driving osteophytes) while preserving physiological signaling required for bone maintenance. The copying approach resolves the contradiction by providing tissue-selective modulation without systemic inhibition.
Data Source
Figure 1~2
Figure 3
Figure 4~5
AI summary
An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain; wherein the isoform is a TGFp-1 agonist. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85 % sequence identity to the sequence set forth in SEQ ID No. 2.